Display options
Cite
Giagulli VA, Silvestrini A, Bruno C, et al. Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism?. Int J Endocrinol. 2020;2020:9649838doi: 10.1155/2020/9649838.
Giagulli, V. A., Silvestrini, A., Bruno, C., Triggiani, V., Mordente, A., & Mancini, A. (2020). Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism?. International journal of endocrinology, 20209649838. https://doi.org/10.1155/2020/9649838
Giagulli, Vito A, et al. "Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism?." International journal of endocrinology vol. 2020 (2020): 9649838. doi: https://doi.org/10.1155/2020/9649838
Giagulli VA, Silvestrini A, Bruno C, Triggiani V, Mordente A, Mancini A. Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism?. Int J Endocrinol. 2020 Jan 21;2020:9649838. doi: 10.1155/2020/9649838. eCollection 2020. PMID: 32411230; PMCID: PMC7201459.
Copy Download .nbib Format: NLM
Share it on

Int J Endocrinol. 2020 Jan 21;2020:9649838. doi: 10.1155/2020/9649838. eCollection 2020.

Is There Room for SERMs or SARMs as Alternative Therapies for Adult Male Hypogonadism?.

International journal of endocrinology

Vito A Giagulli, Andrea Silvestrini, Carmine Bruno, Vincenzo Triggiani, Alvaro Mordente, Antonio Mancini

Affiliations

  1. Internal Medicine, Geriatrics, Endocrinology and Rare Disease, Interdisciplinary Department of Medicine, University of Bari, School of Medicine, Policlinico, Bari, Italy.
  2. Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy.
  3. Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy.

PMID: 32411230 PMCID: PMC7201459 DOI: 10.1155/2020/9649838

Abstract

Hypogonadotropic hypogonadism (HH) can be sustained by organic or functional alterations of the hypothalamic-pituitary-testicular axis. Functional HH is related to systemic alterations, such as obesity or chronic inflammatory diseases, but could contribute to a negative course of the illness. For such situation, according to results obtained in infertile women, the administration of selective estrogen receptor modulators (SERMs) has been proposed in males too, with positive results on both metabolic and sexual function. This class of medications increases gonadotropin levels via antagonism to the estrogenic receptor; similar biological effects are also exerted by aromatase inhibitors (AIs), despite different mechanism of action. After a brief review of trials regarding SERMs and AIs use in male HH, we describe the structure and function of the androgen receptor (AR) as a basis for clinical research about compounds able to bind to AR, in order to obtain specific effects (SARMs). The tissue selectivity and different metabolic fate in comparison to testosterone can potentiate anabolic versus androgenic effects; therefore, they might be a valid alternative to testosterone replacement therapy avoiding the negative effects of testosterone (i.e., on prostate, liver, and hematopoiesis). Trials are still at an early phase of investigation and, at the moment, the application seems to be more useful for chronic disease with catabolic status while the validation as replacement for hypogonadism requires further studies.

Copyright © 2020 Vito A. Giagulli et al.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

References

  1. J Gerontol A Biol Sci Med Sci. 2013 Oct;68(10):1226-35 - PubMed
  2. Sex Med Rev. 2018 Jan;6(1):106-113 - PubMed
  3. J Androl. 1991 Jul-Aug;12(4):258-63 - PubMed
  4. J Urol. 2017 Apr;197(4):1127-1131 - PubMed
  5. J Clin Endocrinol Metab. 1995 Dec;80(12):3689-98 - PubMed
  6. Br J Clin Pharmacol. 2017 Oct;83(10):2179-2194 - PubMed
  7. J Sex Med. 2014 Sep;11(9):2302-7 - PubMed
  8. Bioorg Med Chem Lett. 1998 Apr 7;8(7):745-50 - PubMed
  9. Mol Endocrinol. 1988 Dec;2(12):1265-75 - PubMed
  10. BJU Int. 2016 Dec;118(6):994-1000 - PubMed
  11. Br J Pharmacol. 2008 Jun;154(3):598-605 - PubMed
  12. Psychoneuroendocrinology. 2010 Oct;35(9):1416-21 - PubMed
  13. Mol Cell Endocrinol. 2012 Jul 6;358(1):1-8 - PubMed
  14. J Clin Oncol. 2002 Jul 1;20(13):3001-15 - PubMed
  15. Int J Impot Res. 2003 Jun;15(3):156-65 - PubMed
  16. J Clin Endocrinol Metab. 2016 May;101(5):2040-6 - PubMed
  17. J Clin Endocrinol Metab. 2009 Dec;94(12):4785-92 - PubMed
  18. J Gerontol A Biol Sci Med Sci. 2013 Jan;68(1):87-95 - PubMed
  19. J Clin Endocrinol Metab. 2000 Jan;85(1):219-23 - PubMed
  20. Asian J Androl. 2016 May-Jun;18(3):435-40 - PubMed
  21. PLoS One. 2017 Sep 8;12(9):e0183369 - PubMed
  22. Curr Opin Clin Nutr Metab Care. 2009 May;12(3):232-40 - PubMed
  23. J Med Chem. 1999 Jan 28;42(2):210-2 - PubMed
  24. Andrology. 2013 Sep;1(5):749-57 - PubMed
  25. Lancet Child Adolesc Health. 2019 Feb;3(2):109-120 - PubMed
  26. J Clin Endocrinol Metab. 2010 Apr;95(4):1810-8 - PubMed
  27. J Clin Endocrinol Metab. 2001 Jan;86(1):192-9 - PubMed
  28. J Clin Endocrinol Metab. 2004 Mar;89(3):1174-80 - PubMed
  29. J Sex Med. 2015 Aug;12(8):1761-9 - PubMed
  30. Horm Res. 2009;72(6):321-30 - PubMed
  31. J Clin Endocrinol Metab. 1998 Sep;83(9):3155-62 - PubMed
  32. Endocrinology. 2007 Jan;148(1):363-73 - PubMed
  33. J Musculoskelet Neuronal Interact. 2002 Mar;2(3):222-4 - PubMed
  34. J Clin Endocrinol Metab. 2017 Mar 1;102(3):1067-1075 - PubMed
  35. Nat Med. 2004 Jan;10(1):33-9 - PubMed
  36. J Clin Endocrinol Metab. 1995 Dec;80(12):3546-52 - PubMed
  37. Eur J Med Chem. 2002 Aug;37(8):619-34 - PubMed
  38. Br J Pharmacol. 2008 Jun;154(3):502-21 - PubMed
  39. Andrology. 2018 May;6(3):455-464 - PubMed
  40. J Urol. 2014 Sep;192(3):875-9 - PubMed
  41. J Biol Chem. 2001 Mar 9;276(10):7493-9 - PubMed
  42. J Clin Endocrinol Metab. 2005 Oct;90(10):5717-22 - PubMed
  43. Endocr Pract. 2017 Mar;23(3):279-287 - PubMed
  44. J Clin Endocrinol Metab. 2018 May 1;103(5):1715-1744 - PubMed
  45. Med J Aust. 2016 Sep 5;205(5):228-31 - PubMed
  46. Arch Endocrinol Metab. 2018 Mar-Apr;62(2):227-235 - PubMed
  47. Endocr Rev. 1995 Feb;16(1):87-116 - PubMed
  48. J Cachexia Sarcopenia Muscle. 2011 Sep;2(3):153-161 - PubMed
  49. J Clin Endocrinol Metab. 2015 Feb;100(2):342-62 - PubMed
  50. N Engl J Med. 1996 Mar 14;334(11):707-14 - PubMed
  51. Endocrinology. 2010 Aug;151(8):3706-19 - PubMed
  52. Eur J Endocrinol. 2016 Mar;174(3):R99-116 - PubMed
  53. Biochem Biophys Res Commun. 1998 Mar 6;244(1):1-4 - PubMed
  54. Cancer Lett. 2006 Jan 8;231(1):12-9 - PubMed
  55. Mol Cell Endocrinol. 2013 Apr 30;369(1-2):52-62 - PubMed
  56. Expert Opin Ther Pat. 2009 Sep;19(9):1239-58 - PubMed
  57. Pharmacol Ther. 2019 Aug;200:135-147 - PubMed
  58. J Clin Endocrinol Metab. 2018 Sep 1;103(9):3215-3224 - PubMed
  59. Diabetes Care. 2010 Aug;33(8):1831-3 - PubMed
  60. J Histochem Cytochem. 1993 May;41(5):671-8 - PubMed
  61. J Clin Endocrinol Metab. 1999 Aug;84(8):2647-53 - PubMed
  62. J Clin Endocrinol Metab. 1999 Oct;84(10):3459-62 - PubMed
  63. Endocrinology. 2009 Mar;150(3):1259-68 - PubMed
  64. Mol Endocrinol. 1995 Feb;9(2):208-18 - PubMed
  65. Cancer Res. 2015 Sep 1;75(17):3663-71 - PubMed

Publication Types